Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VaccHemInf: Vaccine Response in HSCT Recipients
NCT03659773Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2018
- Primary completion
- Jan 2021
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Open-label trial of tetanus toxoid, Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated), haemophilus influenzae type b vaccine, Hepatitis B vaccine and influenza vaccine in Tetanus, diphtheria, pneumococcal infection and 3 more (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Proportion of responders defined by the increase in specific antibody titers at 3 months after full block vaccination. Started Apr 2018; status: completed.
02
Drugs
tetanus toxoidCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)haemophilus influenzae type b vaccineHepatitis B vaccineinfluenza vaccine
03
Conditions
Tetanusdiphtheriapneumococcal infectionHaemophilus influenzae type b infection (Hib)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03659773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03659773.